In April 2000, the U.S. Environmental Protection Agency (EPA) nominated four types of in vitro test methods for detecting substances with potential endocrine disrupting activity for review by ICCVAM. These types of test methods were proposed as possible components of the EPA's Endocrine Disruptor Screening Program. NICEATM subsequently compiled available relevant data and prepared a comprehensive background review document for each of the four types of assay. An independent expert panel review concluded that there were no adequately validated in vitro endocrine disruptor screening assays.
Working from the expert panel’s conclusions and recommendations and considering comments from the public, ICCVAM developed recommendations for minimum procedural standards and test methods for future validation of in vitro estrogen receptor (ER) and androgen receptor (AR) binding and transcriptional activation (TA) assays. These recommendations were published in a test method evaluation report, and included:
The ICCVAM report also included a list of 78 reference substances that should be used to standardize and validate these assays. ICCVAM recommended that all 78 substances be used in the validation of each in vitro assay to more accurately assess the predictive value of the assay. ICCVAM also recommended establishment of a central repository of samples of the 78 substances with verified purity. The list of 78 reference substances was subsequently modified because of cost and availability considerations and published in a separate addendum to the test method evaluation report.
Expert Panel Report on the Current Status of In Vitro Test Methods for Detecting Endocrine Disruptors
View minutes from Expert Panel meeting , May 21-22, 2002, RTP, NC
The links listed below connect to pages outside the NTP website. These links are for the convenience of visitors to this page, who may find them useful. NTP is not responsible for the availability or content of these external sites, nor does it endorse, warrant or guarantee any information or any products or services described or offered at these other sites.